Can a simple blood test guide myeloma treatment and spare some patients from transplant?

NCT ID NCT05231629

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized approach for people newly diagnosed with multiple myeloma. After initial treatment, patients are grouped based on whether their cancer is deeply suppressed (MRD-negative) or not. Those with deep response may receive extra drug cycles instead of a stem cell transplant, while others get a transplant plus newer drugs. The goal is to see if this tailored strategy can achieve and maintain the best possible remission.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Daratumumab, bortezomib, lenalidomide, dexamethasone (Dara-VRd) and teclistamab
What this could lead to: If successful, this could help tailor treatment for multiple myeloma patients, potentially allowing some to avoid intensive transplant while maintaining deep remission.
What could go wrong: This is a Phase 2 trial with 300 participants, so results are preliminary. The approach may not improve outcomes for all patients, and side effects from the drug combinations could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Show contact details

Locations

Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States

Contact Email: •••••@•••••
Columbia University
RECRUITING

New York, New York, 10032, United States

Contact Email: •••••@•••••
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Oregon Health and Science University
RECRUITING

Portland, Oregon, 97239, United States

Contact Email: •••••@•••••
University of Alabama at Birmingham
RECRUITING

Birmingham, Alabama, 35233, United States
University of Texas Southwestern
RECRUITING

Dallas, Texas, 75390, United States
University of Utah
RECRUITING

Salt Lake City, Utah, 84112, United States
University of Washington
RECRUITING

Seattle, Washington, 98109, United States
University of Wisconsin - Carbone
RECRUITING

Madison, Wisconsin, 53792, United States

Contact Email: •••••@•••••
Vanderbilt University
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.